(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 August 2010 (12.08.2010)

PCT

(10) International Publication Number
WO 2010/089115 A1

(51) International Patent Classification:
A61K 47/48 (2006.01) *G01N 33/68* (2006.01)

(21) International Application Number:
PCT/EP2010/000689

(22) International Filing Date:
4 February 2010 (04.02.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/GB2009/000301
4 February 2009 (04.02.2009) GB
0913775.3 6 August 2009 (06.08.2009) GB

(71) Applicant *(for all designated States except US)*: **MEDICAL RESEARCH COUNCIL** [GB/GB]; 20 Park Crescent, London W1B 1AL (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **WINTER, Gregory Paul** [GB/GB]; MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH (GB). **HEINIS, Christian** [GB/GB]; MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH (GB). **BERNARD, Elise** [GB/GB]; MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH (GB). **LOAKES, David** [GB/GB]; MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH (GB). **TITE, John Paul** [GB/GB]; 15 High Street, Orwell, Royston, Herts SG8 5QN (GB). **VAYSBURD, Marina** [RU/GB]; MRC Laboratory for Protein Engineering, Hills Road, Cambridge CB2 0QH (GB). **TEUFEL, Daniel Paul** [DE/GB]; MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH (GB).

(74) Agents: **MASCHIO, Antonio** et al.; Edwards Angell Palmer & Dodge Innovations LLP, 10 Carlton Crescent, Southampton SO15 2EZ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2010/089115 A1

(54) Title: MULTISPECIFIC PEPTIDES

(57) Abstract: The invention relates to a method for providing a multispecific peptide ligand comprising a polypeptide covalently linked to a molecular scaffold at three or more amino acid residues and capable of binding to two or more separate targets, comprising the steps of: (a) providing a first repertoire of polypeptides, each polypeptide comprising two or more reactive groups capable of covalent linkage to a molecular scaffold, and at least one loop which comprises a sequence of two or more amino acids subtended between two of said reactive groups; (b) providing a second repertoire of polypeptides as described in (a); (c) joining at least one loop of one or more members of the first repertoire to at least one loop of one or more members of the second repertoire to form at least one polypeptide comprising two loops, and (d) conjugating the composite polypeptide(s) to a molecular scaffold at at least three amino acid positions.